1 – 9 of 9
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Use of Linked Nordic Registries for Population Studies in Hematologic Cancers : The Case of Multiple Myeloma
(
- Contribution to journal › Article
- 2022
-
Mark
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma : A randomised phase 2 trial by the Nordic Myeloma Study Group
(
- Contribution to journal › Article
- 2021
-
Mark
Germline variants at SOHLH2 influence multiple myeloma risk
(
- Contribution to journal › Article
- 2020
-
Mark
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression : A prospective, open-label, multicenter, randomized, phase 3 study
(
- Contribution to journal › Article
- 2018
-
Mark
Chemerin is elevated in multiple myeloma patients and is expressed by stromal cells and pre-adipocytes
(
- Contribution to journal › Letter
- 2013
-
Mark
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
(
- Contribution to journal › Article
- 2010
-
Mark
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial
(
- Contribution to journal › Article
-
Mark
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
(
- Contribution to journal › Article
- 2009
-
Mark
Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial
(
- Contribution to journal › Published meeting abstract